Share
118 Posts.
lightbulb Created with Sketch. 8
clock Created with Sketch.
11/01/18
11:06
Share
Agreed @Marcellus13 ... seems to be all coming together. Right space, right people, right partners, right register. Expecting SP to move accordingly in the coming months.
GLTA holders
Originally posted by Marcellus13
↑
Bod has engaged with highly credible counter parties to source and develop its clinical trial program as follows:
▪ Cannabis extract – globally unique, phytocomplex cannabis extract, sourced from Swiss company Linnea owned by Schwabe and Ipsen (EPA:IPN – Market Cap €8.9Bn)
▪ Delivery method – exclusively sourced from innovative late-stage specialty pharmaceutical company iX Biopharma Ltd (SGX:42C – Market Cap ~SGD$120m)
▪ Clinical trial program – formulation, design and dosage determined by ex-head of global clinical trials of Sirtex Medical Ltd (ASX:SRX – Market Cap ~A$880m)
Our market cap is still sweet FA compared to these other players - could be a long run up from here!
GLTAH
Expand